Sequential therapies for proliferative lupus nephritis.

BACKGROUND Long-term therapy with cyclophosphamide enhances renal survival in patients with proliferative lupus nephritis; however, the beneficial effect of cyclophosphamide must be weighed against its considerable toxic effects. METHODS Fifty-nine patients with lupus nephritis (12 in World Health Organization class III, 46 in class IV, and 1 in class Vb) received induction therapy consisting of a maximum of seven monthly boluses of intravenous cyclophosphamide (0.5 to 1.0 g per square meter of body-surface area) plus corticosteroids. Subsequently, the patients were randomly assigned to one of three maintenance therapies: quarterly intravenous injections of cyclophosphamide, oral azathioprine (1 to 3 mg per kilogram of body weight per day), or oral mycophenolate mofetil (500 to 3000 mg per day) for one to three years. The base-line characteristics of the three groups were similar, with the exception that the chronicity index was 1.9 points lower in the cyclophosphamide group than in the mycophenolate mofetil group (P=0.009). RESULTS During maintenance therapy, five patients died (four in the cyclophosphamide group and one in the mycophenolate mofetil group), and chronic renal failure developed in five (three in the cyclophosphamide group and one each in the azathioprine and mycophenolate mofetil groups). The 72-month event-free survival rate for the composite end point of death or chronic renal failure was higher in the mycophenolate mofetil and azathioprine groups than in the cyclophosphamide group (P=0.05 and P=0.009, respectively). The rate of relapse-free survival was higher in the mycophenolate mofetil group than in the cyclophosphamide group (P=0.02). The incidence of hospitalization, amenorrhea, infections, nausea, and vomiting was significantly lower in the mycophenolate mofetil and azathioprine groups than in the cyclophosphamide group. CONCLUSIONS For patients with proliferative lupus nephritis, short-term therapy with intravenous cyclophosphamide followed by maintenance therapy with mycophenolate mofetil or azathioprine appears to be more efficacious and safer than long-term therapy with intravenous cyclophosphamide.

[1]  Y. Levy,et al.  Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. , 2002, Arthritis and rheumatism.

[2]  M. Petri,et al.  Baseline characteristics of a multiethnic lupus cohort: PROFILE , 2002, Lupus.

[3]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[4]  G. Remuzzi,et al.  Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. , 1997, Kidney international.

[5]  R. Falk,et al.  Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. , 1997, Kidney international.

[6]  A. Steinberg,et al.  Methylprednisolone and Cyclophosphamide, Alone or in Combination, in Patients with Lupus Nephritis , 1996, Annals of Internal Medicine.

[7]  D. Boumpas,et al.  Risk for Sustained Amenorrhea in Patients with Systemic Lupus Erythematosus Receiving Intermittent Pulse Cyclophosphamide Therapy , 1993, Annals of Internal Medicine.

[8]  A. Steinberg,et al.  Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis , 1992, The Lancet.

[9]  E. Lewis,et al.  A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. , 1992, The New England journal of medicine.

[10]  A. Steinberg,et al.  Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. , 1991, Arthritis and rheumatism.

[11]  A. Allison,et al.  Lymphocyte‐Selective Antiproliferative and Immunosuppressive Effects of Mycophenolic Acid in Mice , 1991, Scandinavian journal of immunology.

[12]  G. Appel,et al.  Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. , 1987, The American journal of medicine.

[13]  P H Plotz,et al.  Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. , 1986, The New England journal of medicine.

[14]  L R Muenz,et al.  Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. , 1984, Kidney international.

[15]  V. Pollak,et al.  THE NATURAL HISTORY OF THE RENAL MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 1964, The Journal of laboratory and clinical medicine.

[16]  T. Chan,et al.  Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. , 1995, Nephron.